1496 related articles for article (PubMed ID: 15806331)
1. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
2. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly.
Gilbert JA; Miell JP; Chambers SM; McGregor AM; Aylwin SJ
Clin Endocrinol (Oxf); 2005 Jun; 62(6):742-7. PubMed ID: 15943838
[TBL] [Abstract][Full Text] [Related]
3. Treatment outcomes and mortality of 94 patients with acromegaly.
Trepp R; Stettler C; Zwahlen M; Seiler R; Diem P; Christ ER
Acta Neurochir (Wien); 2005 Mar; 147(3):243-51; discussion 250-1. PubMed ID: 15627919
[TBL] [Abstract][Full Text] [Related]
4. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
[TBL] [Abstract][Full Text] [Related]
5. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.
Carlsen SM; Svartberg J; Schreiner T; Aanderud S; Johannesen O; Skeie S; Lund-Johansen M; Fougner SL; Bollerslev J;
Clin Endocrinol (Oxf); 2011 Jun; 74(6):736-43. PubMed ID: 21521254
[TBL] [Abstract][Full Text] [Related]
6. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
[TBL] [Abstract][Full Text] [Related]
7. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
8. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
Laczi F; Magony S; Julesz J
Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
[TBL] [Abstract][Full Text] [Related]
9. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.
Colao A; Pivonello R; Cavallo LM; Gaccione M; Auriemma RS; Esposito F; Cappabianca P; Lombardi G
Clin Endocrinol (Oxf); 2006 Aug; 65(2):250-6. PubMed ID: 16886969
[TBL] [Abstract][Full Text] [Related]
10. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
11. Long-term basal and dynamic evaluation of hypothalamic-pituitary-adrenal (HPA) axis in acromegalic patients.
Ronchi CL; Ferrante E; Rizzo E; Giavoli C; Verrua E; Bergamaschi S; Lania AG; Beck-Peccoz P; Spada A
Clin Endocrinol (Oxf); 2008 Oct; 69(4):608-12. PubMed ID: 18410544
[TBL] [Abstract][Full Text] [Related]
12. Presurgical octreotide treatment in acromegaly.
Stevenaert A; Beckers A
Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():18-20. PubMed ID: 8372606
[TBL] [Abstract][Full Text] [Related]
13. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
[TBL] [Abstract][Full Text] [Related]
14. A prospective analysis of 151 cases of patients with acromegaly operated by one neurosurgeon: a follow-up of more than 23 years.
Abbassioun K; Amirjamshidi M; Mehrazin A; Khalatbary I; Keynama M; Bokai H; Abdollahi M
Surg Neurol; 2006 Jul; 66(1):26-31; discussion 31. PubMed ID: 16793431
[TBL] [Abstract][Full Text] [Related]
15. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas.
Minniti G; Jaffrain-Rea ML; Osti M; Esposito V; Santoro A; Solda F; Gargiulo P; Tamburrano G; Enrici RM
Clin Endocrinol (Oxf); 2005 Feb; 62(2):210-6. PubMed ID: 15670198
[TBL] [Abstract][Full Text] [Related]
16. Effect of different therapeutic modalities on spontaneous GH secretion in acromegalic patients.
Resmini E; Barreca A; Ferone D; Giusti M; Sidoti M; Minuto F
Clin Endocrinol (Oxf); 2005 Sep; 63(3):294-7. PubMed ID: 16117816
[TBL] [Abstract][Full Text] [Related]
17. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor binding protein-3 levels during early and late follow-up after surgery in acromegalic patients.
Charalampaki P; Hildebrandt G; Schaeffer HJ; Schönau E; Klug N
Exp Clin Endocrinol Diabetes; 1998; 106(2):130-4. PubMed ID: 9628244
[TBL] [Abstract][Full Text] [Related]
19. Evidence supporting surgery as treatment of choice for acromegaly.
Fahlbusch R; Honegger J; Buchfelder M
J Endocrinol; 1997 Oct; 155 Suppl 1():S53-5. PubMed ID: 9389996
[TBL] [Abstract][Full Text] [Related]
20. Gamma knife radiosurgery for acromegaly--long-term experience.
Jezková J; Marek J; Hána V; Krsek M; Weiss V; Vladyka V; Lisák R; Vymazal J; Pecen L
Clin Endocrinol (Oxf); 2006 May; 64(5):588-95. PubMed ID: 16649981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]